Lycia Therapeutics, Inc S-1/A, filed Oct 20, 2026

Lycia Therapeutics, Inc. (LYCA)

Lycia Therapeutics, Inc. is offering 14,700,000 shares at an expected $16.00 to $18.00 per share for its initial public offering and Nasdaq listing under “LYCA.” LCA-0061 showed a mean maximum IgE reduction of 96% from baseline. AI summary